Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Y-mAbs Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
YMAB
Nasdaq
8731
https://www.ymabs.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Y-mAbs Therapeutics Inc
Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet
- Mar 28th, 2024 1:55 pm
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
- Mar 20th, 2024 11:37 am
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
- Mar 14th, 2024 1:05 pm
Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?
- Mar 12th, 2024 1:55 pm
Are You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choice
- Mar 5th, 2024 5:00 pm
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcript
- Mar 4th, 2024 1:45 pm
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
- Mar 4th, 2024 12:30 pm
Y-mAbs Therapeutics Full Year 2023 Earnings: Beats Expectations
- Mar 3rd, 2024 2:40 pm
Q4 2023 Y-mAbs Therapeutics Inc Earnings Call
- Mar 2nd, 2024 2:42 am
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Tops Revenue Estimates
- Feb 29th, 2024 10:25 pm
Y-mAbs Therapeutics Inc (YMAB) Reports Strong Revenue Growth in Q4 and Full Year 2023
- Feb 29th, 2024 9:37 pm
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
- Feb 29th, 2024 9:05 pm
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline
- Feb 22nd, 2024 3:00 pm
CRISPR Therapeutics AG (CRSP) Moves 6.9% Higher: Will This Strength Last?
- Feb 16th, 2024 12:31 pm
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024
- Feb 16th, 2024 12:30 pm
Y-mAbs Therapeutics, Inc. (YMAB) Moves 9.5% Higher: Will This Strength Last?
- Feb 13th, 2024 9:10 am
Here's Why We're Not At All Concerned With Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Situation
- Jan 29th, 2024 7:35 pm
Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Jan 2nd, 2024 9:05 pm
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is definitely on the radar of institutional investors who own 40% of the company
- Jan 2nd, 2024 4:56 pm
Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index
- Dec 13th, 2023 9:05 pm
Scroll